NCT06304545

Treatment of Rectal Cancer With Long-term Concurrent Chemoradiotherapy Combined With Camrelizumab

Long-course Concurrent Chemoradiotherapy Combined With Camrelizumab in the Neoadjuvant Treatment of Locally Advanced/Low Anus-preserving Rectal Cancer: a Phase II Single-arm Study.

• Status: Not Yet Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 48 (estimated)
• Sponsor: Harbin Medical University · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

This is a single-arm, phase II clinical study aim to evaluate the efficacy and safety of long-term concurrent chemoradiotherapy combined with camrelizumab as a neoadjuvant therapy in the treatment of locally advanced/low rectal cancer requiring anus preservation.

Detailed description

This study plans to recruit 48 patients with locally advanced/low anal preservation requiring rectal cancer. The study aims to observe and evaluate the efficacy and safety of long-term concurrent chemoradiotherapy combined with camrelizumab.

Conditions

• Rectal Cancer

Interventions

Type	Name	Description
DRUG	Camrelizumab	Camrelizumab IV 200mg
DRUG	Chemotherapy	Capecitabine PO oxaliplatin IV
RADIATION	Radiotherapy	Radiotherapy 50Gy /45Gy /25 fractions

Timeline

• Start date: 2024-03-15
• Primary completion: 2026-08-16
• Completion: 2027-03-15
• First posted: 2024-03-12
• Last updated: 2024-03-12